신라젠

215600KOSDAQ

54.2 / 100

Reference Date: 2026-09-08

Financial Score15.0 / 40

News Sentiment18.2 / 25

Momentum11.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Rose 6.2% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Shinara Gen is a biotech venture company established in 2006, focusing on developing anti-cancer drugs. The company specializes in oncolytic virus therapies, mitotic checkpoint inhibitors, and generic pharmaceuticals. Its oncolytic viruses selectively target cancer cells and are being studied in combination therapies with immune checkpoint inhibitors.

Number of Employees

56people

Average Salary

82.0M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 15.004.0Point

PBR

3.01Industry Average 1.200.0Point

2.5x industry avg (risky)

ROE

-20.00Industry Average 8.000.0Point

Well below industry avg

Debt Ratio

1.50Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20253.0 / 10 points

Revenue Growth Rate

3.0 / 3

Avg ▲67.3% (2-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼10.5% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -26.0% (improving, 3yr)

Detailed News Sentiment

9 totalPositive 5Neutral 3Negative 1Average Sentiment Score 72.8

Negative
"김승원 식약처 청탁 논란에 구정물 튈라"…제약바이오 신뢰 타격 우.....
신라젠 주가 하락 우려: 김승원 후보자의 식약처 관련 논란으로 제약바이오 산업에 대한 신뢰가 저하되어 부정적 영향 예상.
Neutral
'최경환 의혹 제보' 이철 전 VIK 대표, 명예훼손 2심도 무죄
이철 전 대표의 신라젠 관련 횡령 혐의에 대한 감형 판결은 신라젠 주식에 직접적인 영향을 미치지 않는 것으로 판단됩니다.
Positive
FDA 희귀약 지정에 신라젠 상한가, 한미약품은 기술이전 하루 만에 ...
신라젠이 FDA 희귀약 지정 소식으로 상한가를 기록하며 긍정적인 시장 반응을 보임.

Detailed Momentum

52-week position1.0Point

Near 52w low (17%, downtrend)

Current 2,390Won52-week high 4,97552-week low 1,844

1-month return4.0Point

1m +6.22% (slight rise)

Volume trend6.0Point

Volume surge

Detailed Disclosure

4 totalPositive 0Neutral 4Negative 0

Neutral[기재정정]주식매수선택권부여에관한신고2026-09-03
Neutral[기재정정]주식매수선택권부여에관한신고2026-09-03
Neutral반기보고서 (2026.06)2026-08-14
Neutral[기재정정]분기보고서 (2026.03)2026-08-14